Classification of chronic cough by systematic treatment cascade trial starting with beta agonist
© Shimizu et al.; licensee BioMed Central Ltd. 2013
Received: 30 March 2012
Accepted: 3 February 2013
Published: 7 February 2013
Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators.
The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β2 agonist and second to sub-categorize β2 agonist responsive cough (BRC) by the airway hyperresponsiveness.
One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made.
One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study.
The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan.
University hospital medical information network (UMIN 000007483)
KeywordsAirway hyperresponsiveness β2 agonist Bronchial asthma Cough variant asthma Non-hyperresponsive and β2 agonist responsive cough Gastroesophageal reflex disease Sinobronchial syndrome Atopic cough Postnasal drip Chronic cough
Although cough is the most effective defense mechanism for eliminating foreign materials, including numerous pathogens from the airways, it deteriorates health-related quality of life . Therefore, cough is the most common symptom for which patients seek medical attention .
Chung and Pavord classified the chronic cough into corticosteroid-responsive eosinophilic airway diseases, such as asthma (BA), cough variant asthma (CVA), eosinophilic bronchitis (EB) and corticosteroid resistant disorders such as gastro-esophageal reflux disease (GERD), and the postnasal drip syndrome (PNDS) or rhino-sinusitis . Although all the eosinophilic airway diseases respond to corticosteroid treatment, it is not clear whether these disorders are separate entities, or all one disorder with different levels of severity. Indeed, ~ 30% of CVA is reported to develop into BA [4, 5], suggesting that some types of CVA could be a precursor of BA. On the other hand, some types of PNDS, such as allergic rhinitis and AC, also respond to corticosteroid . Obviously, the prognosis and impact on health-related quality of life from these conditions are quite different from bronchial asthma, and it is not easy to decide how long corticosteroid treatment should be continued. Therefore, investigating how to differentiate corticosteroid-responsive cough from other types of cough is very worthwhile.
Etiological studies of chronic cough vary depending on the clinical setting, the particular interest, the age of patients, and the local definition of diseases [4, 7–10]. For example, sinobronchial syndrome (SBS) is more common in Japan, whereas GERD is less common .
The purposes of this study were to categorize the etiology of chronic cough by its response to the systematic diagnostic treatments starting from a high dose of an inhaled β2 agonist, and secondarily to sub-categorize the β2 agonist responsive cough (BRC) by airway hyperresponsiveness using the methacholine challenge test.
RDs and PRs at step 1 were diagnosed with a β2 agonist responsive cough (BRC). BRC patients who had PC20 of 8 mg/ml or less were classified as having hyperresponsive and β2 agonist responsive cough (HBRC). Among HBRC, patients with a previous history of bronchial asthma or asthmatic symptoms such as episodic wheeze or dyspnea were categorized with bronchial asthma (BA). Patients who had a positive methacholine challenge test without any asthmatic symptoms such as wheezing or dyspnea were diagnosed with cough variant asthma (CVA). Patients without any asthmatic symptoms who failed to undergo the methacholine challenge test were also categorized as CVA. Patients were diagnosed to have non-hyperresponsive BRC (NHBRC) when they responded to the β2 agonist but their PC20 was 20 mg/ml or over. Patients with postnasal drip (PND) and phlegm were diagnosed with sinobronchial syndrome (SBS)  when they responded to the oral administration of clarithromycin and carbocysteine. Patients were diagnosed as atopic cough (AC)  when they had either a high level of serum IgE (>130 IU/ml), or specific IgE antibodies measured by the ELISA method, or other allergic disorders such as allergic rhinitis or food allergy, and responded to oral administration of cetirizine hydrochloride but not to inhaled β2 agonist. Patients were diagnosed with gastroesophageal reflux disease (GERD) when they responded to the oral administration of rabeprazole sodium. NRs to all the treatments at step 1–3 received further examinations such as computed tomography, bronchoscopy, sputum bacteriologies, or serological examinations.
RDs in step 1–3 were selected for a basic comparison. The duration of cough, serum IgE level, a symptom of PND, PC20, %VC, and % FEV1/FVC ratio, and flow volume parameters were compared using ANOVA and post hoc test with Bonferroni correction. Changes in the flow volume parameters of BRCs before and after the airway reversibility test were compared using paired t-test. The magnitude of change in flow volume parameters were compared using ANOVA and post hoc test with Bonferroni correction. A p value less than 0.05 was considered to be significant. All the statistics were performed using StatView5.0 (HULINKS Inc. Tokyo).
Classification of chronic cough
Classification of BRC
BRC 109 (21/88)
BA + SBS
CVA + SBS
NHBRC + SBS
BA + GERD
CVA + GERD
NHBRC + GERD
Classification of non-BRC
Non-BRC 64 (20/44)
AC + SBS + GERD
SBS + GERD
AC + GERD
(n = 19)
(n = 47)
(n = 30)
(n = 17)
(n = 5)
(n = 12)
IgE ( IU/ml)
Functional differences in BRC
Flow volume parameters
In the current study, we found that chronic cough diminished partially or completely in 59% of the patients who used inhaled β2 agonist followed by ICS. The percentage of BRC was higher than that in the previous literature [11, 14], probably because we used the bronchodilator with a higher dose. CVA was the major cause of chronic cough in our study, as previously reported in Japan [15, 16] although this observation is quite different from those in Western countries . In the current study, on the other hand, there was a distinctly different group of patients who responded to beta agonist but did not have airway hyperresponsiveness measured by the methacholine challenge test. We named this condition NHBRC, and it consisted of a significantly large part of BRC (30%) with a higher prevalence in women (Table 1). Fujimoto et al. reported a similar phenomenon in a limited number of patients who responded to a beta agonist without airway hyperresponsiveness . Although the airway reversibility test estimated by the change in FEV1 was not positive in all BRC patients, there was a difference in the flow volume parameters among BA, CVA and NHBRC. A small but significant increase was observed in PEFR after inhalation of salbutamol in BA and CVA, but not in NHBRC (Table 4). There was a significant difference in the magnitude of increase in PEFR between BA and NHBRC (Figure 2). These results suggest that bronchoconstriction or increased smooth muscle tone seem to occur less in NHBRC than in the other BRCs. On the other hand, FEFR50% and FEFR25%, which are used for estimating flow limitation in the peripheral airways, were significantly increased after salbutamol inhalation in all BRC, and the magnitude of increase among BA, CVA and NHBRC was comparable. Since cough diminished after procaterol inhalation in these patients with BRC, bronchoconstriction of peripheral airways may be the common cause of chronic cough. Although bronchoconstriction does not have a direct effect on the sensitivity of the cough receptor in healthy subjects , bronchoconstriction or increased bronchial tone itself may stimulate the afferent tussive nerve, possibly by deformation of the airway epithelium in the peripheral airways . Airway remodeling in BA and CVA has been documented , and similar remodeling could be involved in NHBRC inducing exaggerated airway wall deformation during bronchoconstriction so as to cause chronic cough.
Takemura et al., who compared classical BA and CVA, reported that 15% of CVA patients developed BA after two year observation and that these patients had a higher IgE level than CVA patients who did not develop BA . Their results indicated that the severity of atopic status may be associated with the development of classical asthma with wheezing. Since patients with NHBRC had a significantly higher IgE level as with BA and CVA, it is possible that they could develop CVA or even BA in the future.
As shown in Table 1, there was no combination of diagnoses between BRC and AC. Since ICS was used for BRC in step 1 treatment, and ICS was also effective for AC preventing this combination. Even so, the number of AC patients in our study was far less than was reported by Fujimura et al. . According to the diagnostic criteria of AC , patients with AC do not respond to beta agonist. The dose of beta agonist for diagnosis, however, is not defined. In the current study, twenty out of 33 NHBRC patients were atopic. If the patients with atopic NHBRC in our study were undertreated with β2 agonists, they could well have been diagnosed as AC. Then, the percentage of AC would have become approximately 27%, which is close to the percentage of AC in the previous study by Fujimura et al. . Non-asthmatic eosinophilic bronchitis (NAEB), which shares similar clinical characteristics with AC, is one of the common causes of chronic cough . NAEB is also similar to NHBRC with respect to the effectiveness of ICS and the lack of airway hyperresponsiveness. Since we did not measure the eosinophil counts, it is difficult to speculate whether eosinophilic airway inflammation was involved in NHBRC. On the other hand, the response to beta-agonist has not systematically been investigated in patients with NAEB. Therefore, it seems to be very important to investigate whether there are overlaps between NAEB, AC and NHBRC, since a part of patients with NAEB were reported to develop more serious conditions such as BA or airflow limitation during the few years of follow up .
Postnasal drip syndrome has been recognized as one of the major causes of chronic cough . The guideline issued by the American College of Chest Physicians suggested the use of the term “Upper airway cough syndrome (UACS)” instead of PND . In the current study, we did not categorize the patients as UACS since most of the cough was diagnosed otherwise by the systematic treatment cascade. Although PND was observed in 17-32% of BA, CVA, NHBRC, AC, and GERD patients (Table 3), the cough diminished without H1-antagonist in all groups except for AC. Five out of the 17 ACs had PND (Table 3) and could be diagnosed as having UACS, since both UACS and AC respond to the H1-antagonist, suggesting that there could be an overlap between UACS and AC. Moreover, it is not clear that PND itself is the independent cause of chronic cough since PND from allergic rhinitis or rhinosinusitis is frequently associated with airway disorders such as asthma [27, 28], and the cough diminishes after treatment of asthma. O’Hara and Jones suggested that PND due to rhinosinusitis without a coexistent chest disease is not a predominant cause of chronic cough . In the current study, all the patients with SBS had PND, as well as a productive cough with phlegm, and responded well to the treatment using clarithromycin and carbocysteine suggesting lower airway involvement. Kohno et al. classified the lower airway involvement in SBS into three categories; chronic bronchitis, bronchiectasis, and diffuse panbronchiolitis . Although it is not known why there are more SBS patients in Japan compared with Western countries, the genetic factors may partially contribute to the discrepancy .
GERD is one of the most common causes of chronic cough and is reported to cause up to 41% of it . However, Fujimura et al. reported that only 2% of chronic cough was caused by GERD in Japan . In the current study, 6.5% of chronic cough was caused by GERD alone, and 10.9% of patients had GERD in combination with other disorders (Tables 1 and 2). This result shows that the percentage of GERD is altogether similar to the results in the literature from Western countries . The prevalence of GERD in Japan is increasing since the end of the 1990s [31, 32], possibly due to the change in dietary style and to the decrease in Helicobacter pylori infection brought about by antibiotics treatment. Therefore, the discrepancy between the previous study by Fujimura et al.  and ours could be due to the increasing occurrence of GERD, since our study period was several years later than theirs.
In the current study, we started by diagnosing chronic cough with a bronchodilator. This method is inexpensive and effective for categorizing the etiology of chronic cough. The majority of patients with chronic cough had BRC. NHBRC, a new chronic cough entity, was the major cause of BRC. GERD is a common cause of chronic cough in Japan, as it is in Western countries. AC and SBS are also the causes of chronic cough in Japan.
β2 agonist responsive cough
Hyperresponsive and β2 agonist responsive cough
Non-hyperresponsive and β2 agonist responsive cough
Cough variant asthma
Gastroesophageal reflux disease
Upper airway cough syndrome
Proton pump inhibitor
Angiotensin converting enzyme inhibitor
The authors are grateful to Professor Shuji Hashimoto for his generous assistance with statistical analysis in this study. We are also especially appreciative of Professor Peter D. Paré for his helpful suggestions and support in completing the manuscript.
- Braido F, Baiardini I, Tarantini F, Fassio O, Balestracci S, Pasquali M, Tarchino F, Canonica GW: Chronic cough and QoL in allergic and respiratory diseases measured by a new specific validated tool-CCIQ. J Investig Allergol Clin Immunol. 2006, 16 (2): 110-116.PubMedGoogle Scholar
- Schappert SM, Burt CW: Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat. 2006, 13 (159): 1-66.Google Scholar
- Chung KF, Pavord ID: Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008, 371 (9621): 1364-1374. 10.1016/S0140-6736(08)60595-4.View ArticlePubMedGoogle Scholar
- Fujimura M, Ogawa H, Nishizawa Y, Nishi K: Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma?. Thorax. 2003, 58 (1): 14-18. 10.1136/thorax.58.1.14.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsumoto H, Niimi A, Takemura M, Ueda T, Tabuena R, Yamaguchi M, Matsuoka H, Hirai T, Muro S, Ito Y: Prognosis of cough variant asthma: a retrospective analysis. J Asthma. 2006, 43 (2): 131-135. 10.1080/02770900500498477.View ArticlePubMedGoogle Scholar
- Fujimura M, Ogawa H, Yasui M, Matsuda T: Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy. 2000, 30 (1): 41-47. 10.1046/j.1365-2222.2000.00698.x.View ArticlePubMedGoogle Scholar
- Chang AB, Glomb WB: Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006, 129 (1 Suppl): 260S-283S.View ArticlePubMedGoogle Scholar
- Gibson PG, Dolovich J, Denburg J, Ramsdale EH, Hargreave FE: Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989, 1 (8651): 1346-1348.View ArticlePubMedGoogle Scholar
- Kohno S, Ishida T, Uchida Y, Kishimoto H, Sasaki H, Shioya T, Tokuyama K, Niimi A, Nishi K, Fujimura M: The Japanese Respiratory Society guidelines for management of cough. Respirology. 2006, 11 (Suppl 4): S135-S186.PubMedGoogle Scholar
- McGarvey LP: Cough. 6: Which investigations are most useful in the diagnosis of chronic cough?. Thorax. 2004, 59 (4): 342-346. 10.1136/thx.2004.021832.PubMed CentralView ArticlePubMedGoogle Scholar
- Fujimura M, Abo M, Ogawa H, Nishi K, Kibe Y, Hirose T, Nakatsumi Y, Iwasa K: Importance of atopic cough, cough variant asthma and sinobronchial syndrome as causes of chronic cough in the Hokuriku area of Japan. Respirology. 2005, 10 (2): 201-207. 10.1111/j.1440-1843.2005.00686.x.View ArticlePubMedGoogle Scholar
- Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD: Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000, 161 (1): 309-329.View ArticlePubMedGoogle Scholar
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26 (5): 948-968. 10.1183/09031936.05.00035205.View ArticlePubMedGoogle Scholar
- Morice AH, Fontana GA, Sovijarvi AR, Pistolesi M, Chung KF, Widdicombe J, O’Connell F, Geppetti P, Gronke L, De Jongste J: The diagnosis and management of chronic cough. Eur Respir J. 2004, 24 (3): 481-492. 10.1183/09031936.04.00027804.View ArticlePubMedGoogle Scholar
- Johnson D, Osborn LM: Cough variant asthma: a review of the clinical literature. J Asthma. 1991, 28 (2): 85-90. 10.3109/02770909109082732.View ArticlePubMedGoogle Scholar
- Shirahata K, Fujimoto K, Arioka H, Shouda R, Kudo K, Ikeda S: Prevalence and clinical features of cough variant asthma in a general internal medicine outpatient clinic in Japan. Respirology. 2005, 10 (3): 354-358. 10.1111/j.1440-1843.2005.00709.x.View ArticlePubMedGoogle Scholar
- Niimi A: Geography and cough aetiology. Pulm Pharmacol Ther. 2007, 20 (4): 383-387. 10.1016/j.pupt.2006.10.014.View ArticlePubMedGoogle Scholar
- Fujimoto K, Yamaguchi S, Urushibata K, Koizumi T, Kubo K: Sputum eosinophilia and bronchial responsiveness in patients with chronic non-productive cough responsive to anti-asthma therapy. Respirology. 2003, 8 (2): 168-174. 10.1046/j.1440-1843.2003.00448.x.View ArticlePubMedGoogle Scholar
- Fujimura M, Sakamoto S, Kamio Y, Matsuda T: Effects of methacholine induced bronchoconstriction and procaterol induced bronchodilation on cough receptor sensitivity to inhaled capsaicin and tartaric acid. Thorax. 1992, 47 (6): 441-445. 10.1136/thx.47.6.441.PubMed CentralView ArticlePubMedGoogle Scholar
- Karlsson JA, Sant’Ambrogio G, Widdicombe J: Afferent neural pathways in cough and reflex bronchoconstriction. J Appl Physiol. 1988, 65 (3): 1007-1023.PubMedGoogle Scholar
- Niimi A, Matsumoto H, Minakuchi M, Kitaichi M, Amitani R: Airway remodelling in cough-variant asthma. Lancet. 2000, 356 (9229): 564-565. 10.1016/S0140-6736(00)02584-8.View ArticlePubMedGoogle Scholar
- Takemura M, Niimi A, Matsumoto H, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Chin K, Mishima M: Atopic features of cough variant asthma and classic asthma with wheezing. Clin Exp Allergy. 2007, 37 (12): 1833-1839. 10.1111/j.1365-2222.2007.02848.x.View ArticlePubMedGoogle Scholar
- Brightling CE: Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006, 129 (1 Suppl): 116S-121S.View ArticlePubMedGoogle Scholar
- Berry MA, Hargadon B, McKenna S, Shaw D, Green RH, Brightling CE, Wardlaw AJ, Pavord ID: Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy. 2005, 35 (5): 598-601. 10.1111/j.1365-2222.2005.02222.x.View ArticlePubMedGoogle Scholar
- Palombini BC, Villanova CA, Araujo E, Gastal OL, Alt DC, Stolz DP, Palombini CO: A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest. 1999, 116 (2): 279-284. 10.1378/chest.116.2.279.View ArticlePubMedGoogle Scholar
- Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, Brown KK, Canning BJ, Chang AB, Dicpinigaitis PV: Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006, 129 (1 Suppl): 1S-23S.PubMed CentralView ArticlePubMedGoogle Scholar
- Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, Bousquet J, Chanez P: Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001, 107 (1): 73-80. 10.1067/mai.2001.111593.View ArticlePubMedGoogle Scholar
- Grossman J: One airway, one disease. Chest. 1997, 111 (2 Suppl): 11S-16S.View ArticlePubMedGoogle Scholar
- O’Hara J, Jones NS: The aetiology of chronic cough: a review of current theories for the otorhinolaryngologist. J Laryngol Otol. 2005, 119 (7): 507-514.PubMedGoogle Scholar
- Matsuzaka Y, Tounai K, Denda A, Tomizawa M, Makino S, Okamoto K, Keicho N, Oka A, Kulski JK, Tamiya G: Identification of novel candidate genes in the diffuse panbronchiolitis critical region of the class I human MHC. Immunogenetics. 2002, 54 (5): 301-309. 10.1007/s00251-002-0470-8.View ArticlePubMedGoogle Scholar
- Fujiwara Y, Arakawa T: Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009, 44 (6): 518-534. 10.1007/s00535-009-0047-5.View ArticlePubMedGoogle Scholar
- Mishima I, Adachi K, Arima N, Amano K, Takashima T, Moritani M, Furuta K, Kinoshita Y: Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005, 40 (9): 1005-1009. 10.1080/00365520510023260.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.